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PCoronary Artery Disease
igh-Dose Folic Acid Acutely
mproves Coronary Vasodilator Function
n Patients With Coronary Artery Disease
hmed Tawakol, MD,* Raymond Q. Migrino, MD,† Kusai S. Aziz, MD,* Justyna Waitkowska, MD,*
otfred Holmvang, MD,* Nathaniel M. Alpert, PHD,† James E. Muller, MD,*
lan J. Fischman, MD, PHD,† Henry Gewirtz, MD*
oston, Massachusetts
OBJECTIVES We investigated the acute effect of orally administered high-dose folic acid on coronary
dilator function in humans.
BACKGROUND Folic acid and its active metabolite, 5-methyltetrahydrofolate, increase endothelium-
dependent vasodilation in human peripheral circulation. However, the acute effect on
coronary circulation is not known.
METHODS Fourteen patients with ischemic heart disease, age 62 12 years (mean SD), were enrolled
in a double-blind, placebo-controlled crossover trial. Basal and adenosine-stimulated myo-
cardial blood flow (MBF) were determined by positron emission tomography, and myocardial
flow reserve was calculated. Each patient was studied after ingestion of placebo and after
ingestion of 30 mg folic acid. Myocardial zones were prospectively defined physiologically as
“normal” versus “abnormal” on the basis of MBF response to adenosine 140 g/kg/min
(normal  MBF 1.65 ml/min/g). Abnormal and normal zones were analyzed separately in
a patient-based analysis.
RESULTS Folate was associated with a reduction in mean arterial pressure (100  12 mm Hg vs. 96 
11 mm Hg, placebo vs. folate, p  0.03). Despite the fall in mean arterial pressure, folic acid
significantly increased the MBF dose response to adenosine (p  0.001 using analysis of
variance) in abnormal zones, whereas MBF in normal zones did not change. In abnormal
segments, folic acid increased peak MBF by 49% (1.45  0.59 ml/min/g vs. 2.16  1.01
ml/min/g, p  0.02). Furthermore, folate increased dilator reserve by 83% in abnormal
segments (0.77  0.59 vs. ml/min/g 1.41  1.08 ml/min/g, placebo vs. folate, p  0.05),
whereas dilator reserve in normal segments remained unchanged (2.00  0.61 ml/min/g vs.
2.12  0.69 ml/min/g, placebo vs. folate, p  NS).
CONCLUSIONS The data demonstrate that high-dose oral folate acutely lowers blood pressure and enhances
coronary dilation in patients with coronary artery disease. (J Am Coll Cardiol 2005;45:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.02.0381580–4) © 2005 by the American College of Cardiology Foundation
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Solic acid (folate) is a B vitamin that is required for
ransmethylation reactions, nucleic acid synthesis, homocys-
eine metabolism, and the enzymatic regeneration of tetra-
ydrobiopterin (an essential co-factor of nitric oxide syn-
hase) (1). Previous studies have shown that folate improves
ndothelial function in the peripheral circulation (2), an
ffect that may be independent of homocysteine lowering.
It is not known whether folic acid can acutely improve
oronary dilation in patients with ischemic heart disease.
herefore, we conducted a double-blinded, placebo-
ontrolled crossover study to test the hypothesis that folic
cid improves coronary dilator function in patients with
oronary artery disease. To assess the direct vascular effect of
olic acid independently of its homocysteine-lowering effect,
e studied patients with normal homocysteine concentra-
From the Departments of *Medicine (Cardiac Unit), †Radiology, and Nuclear
edicine, Massachusetts General Hospital, Boston, Massachusetts. This study was
upported, in part, by grants from the National Institutes of Health (RR16046) (to
r. Tawakol) and the American Society of Nuclear Cardiology (to Dr. Tawakol).d
Manuscript received August 20, 2004; revised manuscript received January 5, 2005,
ccepted February 1, 2005.ions and measured myocardial blood flow (MBF) acutely
fter ingestion of folate, before homocysteine lowering
ould occur.
ETHODS
atient population. Adult male and female patients with
oronary artery disease and normal serum homocysteine
oncentration (12 M) were recruited from the greater
oston area. Coronary artery disease was defined as the
resence of a 50% stenosis in at least one coronary artery
dentified by coronary arteriography within the last five
ears. Exclusion criteria included: inability to maintain a
table medical regimen during the study period, concurrent
se of folic acid, or myocardial infarction or coronary
ntervention within the proceeding three months. The study
rotocol was approved by the local human research com-
ittee, and informed consent was obtained from each
ubject.
tudy drug administration. Subjects were enrolled in a
ouble-blinded, placebo-controlled, crossover study during
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May 17, 2005:1580–4 High-Dose Folate Improves Coronary Vasodilationhich folate syrup (30 mg) or similar-tasting placebo syrup
as administered orally in two divided doses, 10 to 12 h and
h before MBF measurements. The 1-h time point and the
ose of 30 mg were chosen to achieve a similar peak plasma
-methyltetrahydrofolate level (3) (the biologically active
orm of folic acid) that has previously been shown to
mprove peripheral nitric oxide-mediated vasodilation (1).
olate and placebo were administered at least one week
part, in random order, and in a double-blinded manner.
BF measurements. Vasoactive medications were with-
eld for three to five half-lives, and subjects were asked to
void caffeinated beverages for 24 h before blood flow
easurements; MBF was assessed with positron emission
omography (PET) (GE Medical Systems Scanditronix
C4096, Chalfont St. Giles, United Kingdom) approxi-
ately 1 h after ingestion of the second dose of the study
rug. Positron emission tomography measurements of MBF
13N-ammonia method) were performed at rest and during
he infusion of two doses of adenosine (70 and 140
g/kg/min), using a previously described method (4).
ET image analysis. Three short-axis rings corresponding
o the proximal, middle, and distal thirds of the left ventricle
ere constructed for each K1 scan, and MBF was measured
ithin 24 standard areas of interest as described previously
4). Data analysis was performed without knowledge of
reatment order. To determine the variability of the MBF
easurements, two readers independently assessed
denosine-stimulated MBF in 120 segments in five subjects,
nd the difference between and within readers was calcu-
ated. The mean ( SD) intra- and interobserver difference
as 0.03  0.10 ml/min/g and 0.03  0.17 ml/min/g,
espectively.
rospective definition of myocardial zones. We prospec-
ively sought to examine MBF in regions supplied by
tenotic conduit vessels (which were expected to have
bnormal dilator capacity) separately from regions with
ormal dilator capacity. Data obtained in our laboratory
emonstrate that maximal MBF 1.65 ml/min/g with
igh-dose adenosine has very high negative predictive ac-
uracy (91%) for exclusion of moderate-to-severe coronary
rtery stenosis and that 97% of moderate-to-severe stenoses
ad maximal MBF 1.65 ml/min/g (5). Accordingly,
yocardial zones were physiologically as “normal” versus
abnormal” on the basis of MBF response to adenosine 140
g/kg/min (Ado 140) during the placebo condition. Myo-
ardial zones with MBF with Ado 140 of 1.65 ml/min/g
during placebo condition) were defined as abnormal. The
orresponding myocardial regions were identified during the
Abbreviations and Acronyms
Ado 140  adenosine 140 g/kg/min
MBF  myocardial blood flow
PET  positron emission tomographyolate condition and were labeled abnormal regardless of pheir MBF during the folate condition. Values for abnormal
BF were combined and averaged to obtain a single value
f abnormal blood flow for each patient at each condition
placebo and folic acid) for each scan acquisition (rest,
denosine 70 or adenosine 140). A patient-based analysis of
BF was performed.
Dilator reserve for both normal and abnormal zones was
efined as the difference between peak MBF and rest MBF.
eak MBF was defined as the higher of the two average
BF values obtained during adenosine (i.e., the greater of
he average MBF obtained during adenosine 70 vs. adeno-
ine 140 dose). This was done, because in patients with
schemic heart disease, coronary “steal” may occur (6) and cause
nderestimation of dilator reserve in abnormal regions.
oronary angiography. Coronary angiograms were re-
iewed in blinded fashion by an expert (G.H.) for the
resence and grade of collaterals as previously described (6).
tatistical analysis. Data are expressed as mean values 
D. A repeated-measures analysis of variance (ANOVA)
as performed (Statview v 4.0, Abacus Concepts, Cary,
orth Carolina), with terms for the order of folate versus
lacebo administration, patient, and observations (blood
ressure and MBF) for the three repeated measurements
adenosine 0, 70, and 140). To control for multiple testing,
rospectively defined pairwise t tests comparing folate to
lacebo at each of the three adenosine doses were performed
nly if there was a significant main effect for folate or a
ignificant interaction of folate with adenosine in the
NOVA analysis. Values of p  0.05 were considered
ignificant.
ESULTS
ubject characteristics. A total of 14 patients were stud-
ed. Subject characteristics are displayed in Table 1.
emodynamics. Hemodynamic parameters are displayed
n Table 2. There was no significant change in heart rate or
ate-pressure product (folate vs. placebo) (Table 2, Fig. 1).
owever, folate caused a significant reduction in systolic,
iastolic, and mean arterial blood pressures (p  0.01 using
NOVA, Table 2). An order effect for placebo versus folate
as never significant for any of the analyses of variance for
he hemodynamic (or any other) measurements.
BF. In normal regions, folate did not affect MBF (Table
). However, in abnormal zones, despite the fall in mean
rterial pressure, folic acid significantly increased the MBF
esponse to adenosine (p 0.001 using ANOVA, Table 3).
his was accompanied by a 49% increase in peak MBF in
bnormal zones (1.45  0.59 ml/min/g vs. 2.16  1.01
l/min/g, placebo vs. folate p  0.02; Table 3, Fig. 2).
urthermore, folate increased dilator reserve by 83% in
bnormal segments (0.77  0.59 ml/min/g vs. 1.41  1.08
l/min/g, placebo vs. folate, p  0.04; Table 3, Fig. 3),
hereas dilator reserve in normal segments remained un-
hanged (2.00  0.61 ml/min/g vs. 2.12  0.69 ml/min/g,
lacebo vs. folate, p  NS).
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High-Dose Folate Improves Coronary Vasodilation May 17, 2005:1580–4The ratio of MBF in abnormal versus normal zones was
etermined for each patient during each condition. There
as a significant improvement in the abnormal/normal
BF ratio at rest and during adenosine after folate (Table
). Notably, peak MBF increased in the abnormal zones
elative to the normal zones in 85% of patients (Fig. 4).
imilarly, dilator reserve increased in the abnormal zones
elative to the normal zones in 83% of patients.
able 1. Subject Characteristics (Mean  SD)
Characteristic Value
ender (M/F) 13/1
ge (yrs) 62  12
iabetes (% subjects) 20
moking (% subjects) 57
Current 7
Former 50
BP (mm Hg) 125  12
BP (mm Hg) 74  7
otal cholesterol (mg/dl) 155  30
DL (mg/dl) 88  27
DL (mg/dl) 41  8
riglycerides (mg/dl) 130  79
tatin use (% subjects) 100
eta-blocker use (% subjects) 80
alcium antagonist use (%) 7
omocysteine (mol/l) 8.7  1.5
oronary disease (% subjects)
One-vessel 29
Two-vessel 21
Three-vessel 50
rior CABG (% subjects) 43
rior MI (% subjects) 36
ABG  coronary artery bypass grafting; DBP  diastolic blood pressure; HDL 
igh-density lipoprotein; LDL  low-density lipoprotein; MI  myocardial infarc-
ion; SBP  systolic blood pressure.
Table 2. Effect of Folate on Hemodynamic Va
Place
HR (beats/min)
Rest 61 
Ado 70 68 
Ado 140 82 
RPP (mm Hg  beats/min)
Rest 7,617 
Ado 70 9,074 
Ado 140 10,444 
SBP (mm Hg)*
Rest 125 
Ado 70 131 
Ado 140 127 
DBP (mm Hg)*
Rest 75 
Ado 70 74 
Ado 140 75 
MAP (mm Hg)*
Rest 100 
Ado 70 103 
Ado 140 101 
*p  0.05 analysis of variance for adenosine dose-response c
Ado 70  adenosine 70 g/kg/min; Ado 140  adenosine 140
rate; MAP  mean blood pressure; RPP  rate-pressure productoronary anatomy. A total of 94% of myocardial zones
hat were classified as abnormal by PET were found to be
ubserved by stenotic coronary arteries (70% stenoses).
ollaterals of varying grade (I to III) were observed supply-
ng the abnormal zones in 9 of 13 patients. Of the 10
atients in whom abnormal zone MBF improved after
olate, 8 had collaterals to the abnormal zone. In contrast, of
hree patients in whom abnormal zone MBF failed to
mprove after folate, only one of three exhibited collaterals
o the abnormal zone. Sample size was insufficient to
etermine if peak MBF response correlated with collateral
rade.
iochemical data. Total plasma folate levels increased
ignificantly after folic acid ingestion (20  6 ng/ml vs. 473
106 ng/ml, placebo vs. folate, p  0.01). Conversely,
es (Mean  SD)
Folate p Value
61  8 NS
70  14 NS
82  15 NS
7,483  1,798 NS
8,604  2,484 NS
9,998  3,066 NS
121  15 NS
123  18 NS
120  21 NS
70  9 0.01
68  11 0.04
69  10 0.01
96  11 0.03
95  13 0.01
95  15 0.03
placebo vs. folate conditions).
igure 1. Effect of high-dose folate on mean arterial pressure (MAP).
esting MAP was measured. Individual responses are shown, and group
ean data ( SD) are depicted by the thick line. Folate significantly
educed MAP (100  3 mm Hg vs. 96  2 mm Hg, placebo vs. folate,
 0.03).riabl
bo
9
13
13
1,717
2,639
2,156
18
21
14
9
12
12
12
15
14
urve (
g/kg/min; DAP  diastolic blood pressure; HR  heart
(systolic blood pressure [SBP]  HR).
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May 17, 2005:1580–4 High-Dose Folate Improves Coronary Vasodilationlasma homocysteine concentrations did not change after
olic acid (7.1  1.4 mol/l vs. 7.8  1.1 mol/l, placebo
s. folate, p  NS).
ISCUSSION
he important new findings in this study are that high-dose
olic acid: 1) increases both vasodilator-stimulated MBF as
ell as flow reserve in myocardial segments with impaired
able 3. Effect of Folate on MBF (Mean  SD)
Placebo Folate p Value
MBF (ml/min/g)
bnormal*
Rest 0.68  0.24 0.74  0.27 NS
Ado 70 1.30  0.71 1.60  1.15 NS
Ado 140 1.18  0.32 1.76  0.75 0.03
Peak 1.45  0.59 2.16  1.01 0.02
ormal
Rest 0.84  0.29 0.81  0.19 NS
Ado 70 2.10  0.97 2.01  0.88 NS
Ado 140 2.78  0.67 2.72  0.74 NS
Peak 2.84  0.61 2.86  0.67 NS
atio ABN:WNL*
Rest 0.80  0.15 0.95  0.17 0.03
Ado 70 0.67  0.16 0.84  0.37 NS
Ado 140 0.47  0.15 0.67  0.21 0.02
Peak 0.54  0.17 0.75  0.24 0.01
Dilator Reserve (ml/min/g)
bnormal 0.77  0.59 1.41  1.08 0.04
ormal 2.00  0.61 2.12  0.69 NS
atio ABN:WNL 0.43  0.21 0.63  0.36 0.01
p  0.05 Analysis of variance for adenosine dose-response curve (placebo vs. folate
onditions).
ABN  abnormal; Abnormal  myocardial segments with abnormal dilator
apacity during placebo condition; Ado 70  adenosine 70 g/kg/min; Ado 140 
denosine 140 g/kg/min; Normal  myocardial segments with normal dilator
apacity during placebo condition; Ratio Abnormal/Normal zone myocardial blood
ow (MBF); WNL  normal.
igure 2. Effect of high-dose folate on peak (adenosine-stimulated)
yocardial blood flow (MBF). Peak adenosine-stimulated MBF was
easured in abnormal zones. Individual responses are shown, and group
ean data are depicted by the thick line. Folate significantly increasedeak MBF (1.45  0.59 ml/min/g vs. 2.16 1.01 ml/min/g, mean SD,
lacebo vs. folate, p  0.02).
t
0ilator function; and 2) acutely lowers arterial pressure
ndependently of homocysteine lowering. As such, this
tudy extends observations of folate’s effects made in the
eripheral circulation to the coronary circulation, and high-
ights a potentially useful clinical role for folic acid in the
herapy of ischemic heart disease.
echanism of the vasodilator effect of folic acid. Previ-
us studies have demonstrated that folate enhances nitric oxide
ioavailability (2,7). We and others (8) have previously shown
hat nitric oxide plays a significant role in adenosine-induced
asodilation in the coronary microcirculation. It is plausible,
herefore, that in the current study, the increase in adenosine-
nduced blood flow that occurred after folate ingestion is also a
esult of increased nitric oxide bioavailability.
ascular locus of folate’s effects. In the current study,
oth MBF (Fig. 2) and dilator reserve (Fig. 3) increased in
igure 3. Effect of high-dose folate on coronary dilator reserve. Dilator
eserve was measured in normal (WNL) and abnormal (ABNL) regions.
ean data and standard error bars are depicted. Folate increased dilator
eserve by 83% in abnormal segments (0.72  0.60 ml/min/g vs. 1.31 
.08 ml/min/g, mean  SD, placebo vs. folate, p  0.05), whereas dilator
eserve in normal segments remained unchanged (2.00 0.61 ml/min/g vs.
.12  0.69 ml/min/g, placebo vs. folate, p  NS). Open bars  placebo;
olid bars  folate.
igure 4. Effect of high-dose folate on peak flow ratio. The ratio for peak
yocardial blood flow, in abnormal relative to normal segments, is shown for
ach patient. Group mean data are depicted by the thick line. Folate increased
he ratio of flow in abnormal segments relative to normal segments (0.54 
.17 vs. 0.75  0.24, mean  SD, placebo vs. folate, p  0.01).
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High-Dose Folate Improves Coronary Vasodilation May 17, 2005:1580–4egions with abnormal flow reserve after folate, a finding
hat is all the more noteworthy because diastolic blood
ressure (coronary perfusion pressure) was significantly
ower with folate (Table 2). The exact vascular locus of
olate’s effects cannot be determined from the results of this
tudy. Myocardial dilator capacity is impaired in collateral-
ependent areas (9) in regions supplied by stenotic conduit
essels (5) and in resistance vessels distal to a stenosis
10,11). Thus, the potential for folate to improve vasomo-
ion exists for any of these vessels.
bservation that folate reduces systemic blood pressure.
revious studies have demonstrated blood pressure lowering
n the setting of long-term folate (four weeks to two years)
n association with homocysteine lowering (12,13). In the
urrent study, we observed a significant reduction in blood
ressure after the ingestion of folate in 11 of 14 patients that
ccurred in the absence of changes in homocysteine con-
entration. As was postulated as the mechanism for folate’s
ffects on the coronary circulation, the reduction in systemic
lood pressure observed after folate administration may
esult from enhanced nitric oxide bioavailability.
tudy limitations. Two important limitations of this study
hould be noted. First, the study examined only acute effects
f folate. Therefore, it is not known if long-term, high-dose
olate therapy will have similar effects. Second, only one
emale patient was included in the study group. Accord-
ngly, these results may not be generalizable to women.
linical implications. We observed a 5-mm Hg reduction
n diastolic blood pressure with folate. Previous meta-
nalyses have demonstrated that a 5- to 6-mm Hg reduction
n diastolic blood pressure is clinically significant and is
ssociated with significant reductions in stroke (14,15) and
eart disease (14). Should future studies demonstrate that
olate’s antihypertensive effect is sustained with long-term
se, then folic acid might prove to be a valuable addition to
n antihypertensive therapy.
We also observed a significant increase in flow reserve.
ecause abnormalities in MBF and flow reserve are associated
ith manifestation of ischemia in patients with coronary artery
isease (16), it follows logically that high-dose folate may
educe the occurrence of ischemia in patients with coronary
isease. However, there are only limited data demonstrating
hat pharmacologic interventions that acutely improve MBF
nd flow reserve have a significant long-term effect on angina.
ccordingly, the potential for folate-mediated cardiovascular
enefits is theoretical but unproven.
The current study demonstrates that folic acid has acute
asodilating actions that occur in the absence of homocysteine
owering. Accordingly, the findings of the current study raise
wo possibilities that may impact the interpretation of on-
oing trials: 1) doses of folate that are significantly higher than
mployed in previous trails may impart additional cardiovas-
ular benefits; and 2) the vascular benefits of folic acid may
xtend beyond its homocysteine-lowering effect.
onclusions. This study demonstrates that oral folatecutely enhances coronary dilation and modestly lowersrterial pressure in patients with coronary artery disease.
hese findings extend observations of effects of folate made
n the peripheral circulation to the coronary circulation.
urther, this study demonstrates an effect of folic acid on
ascular function that is independent of its effect on homo-
ysteine lowering and raises the possibility that administer-
ng doses of folic acid that are higher than previously
mployed may confer additional clinical benefits.
eprint requests and correspondence: Dr. Ahmed Tawakol,
ardiac Unit/Vincent Burnham 3, Massachusetts General Hospi-
al, Boston, Massachusetts 02114. E-mail: atawakol@partners.org.
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